Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Robust Biomarker of Aggressive HCC and the Response for Adjuvant PD-1 Inhibitors or Combined TKIs Following Liver Resection: Vessels That Encapsulate Tumor Clusters

NCT06253364 is registered in ClinicalTrials.gov with Chen Xiaoping as lead sponsor.

NCT NCT06253364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Robust Biomarker of Aggressive HCC and the Response for Adjuvant PD-1 Inhibitors or Combined TKIs Following Liver Resection: Vessels That Encapsulate Tumor Clusters
Lead sponsor
Chen Xiaoping
Phase
Observational
Overall status
Completed
Start date
January 1, 2019
Completion date
January 31, 2024
Enrollment
462 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, recurrence